Novartis AG research snapshot
NVS AI stock analysis sees Novartis as a focused innovative-medicines company that returned to sales growth in the second quarter of 2026 while its heart-failure medicine Entresto faces generic erosion in the United States. At the August 2, 2026 data cutoff, NVS closed at $156.15 on July 31 and the mechanically verified market capitalization was $297.39 billion. The investment case rests on priority brands such as Kisqali, Cosentyx, Kesimpta, Pluvicto, Leqvio and Scemblix, plus three major pipeline readouts due in the second half, set against drug-pricing pressure, patent cliffs, deal risk and a valuation near the average analyst target. This NVS AI stock analysis is an informational research tool, not investment advice.
Current price
$156.15
Market cap
$297.39 billion
AI score
74 / 100
Rating
Quality innovative-medicines business, modest growth and a valuation near consensus target
Trend status
Above the 50-day and 200-day averages, consolidating below $160 recent highs
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Novartis develops and commercializes prescription medicines, converting clinical evidence, regulatory approvals, manufacturing, and field access into recurring revenue from specialty therapies. | High |
| Moat | Patents, clinical data, regulatory know-how, physician relationships, manufacturing quality, and global distribution create meaningful barriers, although each franchise eventually faces competition. | Medium-high |
| Management | CEO Vas Narasimhan has said he will stay for the next growth phase. The team should be judged on portfolio renewal, R&D productivity, disciplined bolt-on deals below $2 billion upfront, buybacks, and execution of H2 pipeline readouts. | Medium |
| Financial trend | Q2 2026 net sales rose about 1% in constant currency to $14.4 billion with core EPS of $2.41, core operating income flat at $5.9 billion, and free cash flow of $5.6 billion. Full-year guidance calls for low single digit sales growth and a low single digit core operating income decline. | High |
| Valuation | At $156.15, NVS traded near 23.3x trailing earnings and about 17.7x free cash flow with a forward P/E near 16.95, which is close to the $155.37 average analyst target and leaves limited margin for execution misses. | Medium-high |
| Technical trend | NVS held above the cited 50-day and 200-day moving averages with an RSI near 53, describing a neutral momentum reset while the stock consolidates below the $160 recent highs. | Medium |
| Risk level | Risk is medium because of US generic erosion at Entresto, three late-stage H2 trial readouts, drug-pricing pressure, clinical and regulatory uncertainty, foreign exchange, acquisitions, and the cost of replenishing the portfolio. | Medium-high |
| AI confidence | Reported data is well documented, but AI cannot establish the probability or commercial value of future trial outcomes, patent disputes, and payer decisions. | High data confidence |
| Investment certainty | Medium certainty. NVS has a credible quality case, but the margin of safety depends on whether priority brands and launches keep replacing mature-product pressure and on how H2 readouts land. | Medium |
NVS AI stock forecast
The NVS AI stock forecast uses scenario ranges instead of a precise price promise. The three-year model was calculated with financial_rigor.py using $156.15, $6.61 trailing EPS, and differentiated growth and terminal multiple assumptions. Analyst consensus also showed a $155.37 average target, a $123 to $180 range, and a Hold rating near the cutoff, which is a reference point rather than a forecast guarantee.
$245 to $265 over three years
More likely if priority brands and launches keep growing high single to double digits, the three H2 pipeline readouts convert into durable revenue, margins hold, and investors maintain a premium multiple near 28x earnings.
$165 to $185 over three years
More likely if EPS grows in the mid single digits, Entresto erosion is absorbed, guidance is met, and the market values NVS near 22x earnings as consensus projects.
$95 to $110 over three years
More likely if generic or biosimilar pressure accelerates, the H2 readouts disappoint, pricing weakens further, acquisitions dilute returns, or the valuation compresses toward 15x earnings.
NVS AI technical analysis
NVS AI technical analysis was constructive but not decisive at the August 2, 2026 cutoff. StockAnalysis listed a $156.15 close on July 31, a 50-day moving average of $152.56, a 200-day moving average of $146.27, RSI of 53.08, and 20-day average volume of 1.78 million shares. Confirm all levels with a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $156.15 | NYSE closing price on July 31, 2026, used as the August 2 research cutoff snapshot. |
| Near support | $152.50 to $153 | The cited 50-day moving average was $152.56, making this the first trend-support area to monitor. |
| Major support | $146 to $147 | The cited 200-day moving average was $146.27. A sustained break below it would weaken the long-term trend. |
| Near resistance | $159.85 to $160.60 | This zone covers the July 28 closing high and the July 2 intraday high in the cited price history. |
| 50-day moving average | $152.56 | StockAnalysis statistics listed this average at the cutoff. |
| 200-day moving average | $146.27 | Price remained above this average at the cutoff, supporting the longer-term trend view. |
| Momentum | RSI 53.08 | The cited RSI was near neutral, so it did not by itself confirm an overbought or oversold setup. |
| Volume | 1.78 million average shares | StockAnalysis listed 20-day average volume near 1.78 million shares. Breakouts need volume confirmation. |
| Volatility | Low beta, event-sensitive | The cited five-year beta was 0.50, but earnings, clinical data, regulation, and deal news can still produce gaps. |
| Invalidation | Close below $152.50, then $146 | A close below the 50-day average weakens the short-term setup. A break below the 200-day average calls for a new thesis review. |
NVS AI trading strategy
The NVS AI trading strategy is a rules-based research framework, not personalized advice. Use live prices, position sizing, loss limits, earnings dates, regulatory calendars, and current Novartis filings before placing a trade.
Watch for NVS to hold the $152.50 to $153 support area and reclaim the $159.85 to $160.60 resistance zone with volume that confirms demand, ideally after a positive H2 pipeline or approval event.
A close below $152.50 or a failed breakout after a material company update should invalidate the short-term setup.
If NVS pulls back toward the 50-day or 200-day average without a new trial, pricing, or guidance problem, compare the price action with priority-brand sales and portfolio-replacement evidence.
Do not average down without a defined maximum loss because generic, regulatory, and clinical events can change the business case quickly.
Track Kisqali, Cosentyx, Kesimpta, Pluvicto, Leqvio and Scemblix sales, Entresto erosion, core operating margin, the three H2 readouts, deals such as Myricx Bio, net debt, dividends, and buybacks.
Reduce confidence if apparent earnings resilience depends on one-off phasing items, debt-funded capital returns, or launches that do not replace expected losses of exclusivity.
Investment research summary
Novartis sells differentiated prescription medicines. Customers pay for therapies with clinical evidence and regulatory approval that can improve outcomes in serious chronic and specialty diseases.
The moat rests on patents, clinical and real-world evidence, scientific expertise, regulatory capability, manufacturing quality, global commercial access, and physician trust. It is valuable but finite because drug exclusivity expires.
The thesis can fail if US generic erosion at Entresto spreads to other products before launches scale, the H2 readouts disappoint, payer and government price pressure rises, acquisitions destroy value, or buybacks and debt constrain flexibility.
Management must keep renewing the portfolio while balancing internal R&D, licensing, acquisitions, dividends, and buybacks. The important test is whether capital deployed today creates durable post-patent cash flows.
Aging populations and better diagnosis support demand for specialty medicines, but the same markets face tighter reimbursement, regulatory review, scientific competition, and political scrutiny of drug prices.
The verified valuation reflects a profitable, cash-generative pharmaceutical business that trades near the average analyst target. The margin of safety improves only if portfolio renewal and earnings growth outpace mature-product erosion.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| NVS price | $156.15 closing price on July 31, 2026 | StockAnalysis historical price data, sourced from S&P Global Market Intelligence | August 2, 2026 |
| Market capitalization | $297.39 billion, verified as $156.15 x 1.904 billion implied shares, a 0.03% deviation | StockAnalysis market-cap snapshot and financial_rigor.py market-cap verification | August 2, 2026 |
| Q2 2026 operating results | $14.4 billion net sales (up about 1% constant currency), core EPS $2.41, core operating income flat at $5.9 billion, and free cash flow $5.6 billion. | Novartis Q2 2026 results reported July 21, 2026, via MarketBeat earnings call coverage | August 2, 2026 |
| FY 2025 net sales | StockAnalysis standardized financials list $56.67 billion; Novartis reported net sales were about $54.53 billion, a 1.92% difference that may reflect data standardization or scope. | Novartis annual results and StockAnalysis cross-check | August 2, 2026 |
| Trailing twelve month financials | $56.69 billion revenue, $12.76 billion net income, $6.61 EPS, and $16.76 billion free cash flow. | StockAnalysis statistics and income statement data | August 2, 2026 |
| Valuation ratios | PE ratio 23.31, forward PE 16.95, price to sales 5.25, price to book 7.09, and price to FCF 17.74. | StockAnalysis statistics table | August 2, 2026 |
| Cash and debt | $7.62 billion cash and cash equivalents, $49.01 billion total debt, and net cash of negative $41.40 billion at the trailing cutoff. | StockAnalysis balance-sheet data | August 2, 2026 |
| Technical indicators | 50-day moving average $152.56, 200-day moving average $146.27, RSI 53.08, and 20-day average volume 1.78 million shares. | StockAnalysis statistics table | August 2, 2026 |
| Analyst consensus | Hold rating from 12 analysts with a $155.37 average target, ranging from $123 to $180. | StockAnalysis forecast and analyst ratings data | August 2, 2026 |
This page is an informational research tool, not investment advice or a recommendation to buy or sell any security. Forecast ranges are scenarios based on available data and assumptions. They can be wrong, and readers should verify current information and consider their own objectives and risk tolerance.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
